Anova Enterprises
Anova is a technology company dedicated to accelerating clinical development, reducing costs, and increasing access to promising new treatments through its innovative AnovaOS™ platform. The platform connects research sponsors, sites, physicians, and patients globally, enabling rapid study activation, patient matching, and data collection to speed the development of complex treatments across various medical fields. Anova aims to transform the traditional clinical trial landscape by fostering a patient-focused, collaborative, and efficient research environment.
Industries
Nr. of Employees
small (1-50)
Anova Enterprises
Arlington Heights, Illinois, United States
Products
Clinical research technology platform (registry, matching, activation)
A platform that aggregates sponsor and study registries, site and investigator profiles, and enables patient-to-trial matching, rapid site activation and integrated data capture to support clinical trials and expanded access programs.
AnovaOS
An integrated technology platform and research network that connects sponsors, sites, and physicians to streamline study feasibility, patient matching, site activation, clinical trial enrollment, compassionate use, and data capture.
Clinical research technology platform (registry, matching, activation)
A platform that aggregates sponsor and study registries, site and investigator profiles, and enables patient-to-trial matching, rapid site activation and integrated data capture to support clinical trials and expanded access programs.
AnovaOS
An integrated technology platform and research network that connects sponsors, sites, and physicians to streamline study feasibility, patient matching, site activation, clinical trial enrollment, compassionate use, and data capture.
Services
Consulting services for clinical development programs and technical support for data integration, advanced analytics and evidence generation.
Design and operational management of early-access and compassionate use programs, including application workflows, data collection and program oversight.
Operational delivery of clinical studies including feasibility, rapid site activation, enrollment management, monitoring and start-up activities for early-phase studies.
Preparation of regulatory designation requests and submission materials (e.g., Fast Track, orphan and pediatric designation support) and coordination of regulatory interactions.
Technical services for integrating disparate clinical and real-world data sources and applying analytics to generate evidence and inform development decisions.
Consulting services for clinical development programs and technical support for data integration, advanced analytics and evidence generation.
Design and operational management of early-access and compassionate use programs, including application workflows, data collection and program oversight.
Operational delivery of clinical studies including feasibility, rapid site activation, enrollment management, monitoring and start-up activities for early-phase studies.
Preparation of regulatory designation requests and submission materials (e.g., Fast Track, orphan and pediatric designation support) and coordination of regulatory interactions.
Technical services for integrating disparate clinical and real-world data sources and applying analytics to generate evidence and inform development decisions.
Expertise Areas
- Clinical trial management
- Expanded access and compassionate use programs
- Real-world data (RWD) and real-world evidence (RWE) generation
- Digital health platforms for patient-trial matching
Key Technologies
- Patient-to-trial matching algorithms
- Centralized study and sponsor registry
- Electronic data capture and master data management
- Real-world data collection and RWE analytics
News & Updates
The CEO Christopher Beardmore presented a new approach to Compassionate Use at the summit in Washington, DC.
Discussion of FDA plans to facilitate access to unapproved therapies through streamlined processes.
Announcement of the first patient enrollment in a clinical trial for DB107, a treatment for high-grade gliomas.
Partnership to develop DZD9008 for NSCLC with EGFR Exon20 insertion mutation.
The CEO Christopher Beardmore presented a new approach to Compassionate Use at the summit in Washington, DC.
Discussion of FDA plans to facilitate access to unapproved therapies through streamlined processes.
Announcement of the first patient enrollment in a clinical trial for DB107, a treatment for high-grade gliomas.
Partnership to develop DZD9008 for NSCLC with EGFR Exon20 insertion mutation.